Lung Cancer

We now have more tools than ever in the fight against tobacco-related death and disability, but unfortunately, there is not equal access to resources for smoking cessation, early lung cancer diagnosis, and treatment.

Treatment optimization for centrally located lung cancers requires special considerations for determining resectability and patient selection.

In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.

A breath test that looks for carbonyl volatile organic compounds could help distinguish between benign and malignant nodules, and be used as an adjunct to CT scans in lung cancer diagnosis.

A study in mice showed that antioxidant supplementation increases tumor progression and reduced survival in Braf- and Kras-induced lung cancer.

The use of a microRNA signature classifier assay was found to have high predictive, diagnostic, and prognostic value in a lung cancer screening trial in Italy. Adding the plasma microRNA test to low-dose CT screening reduced false positive rates.

In this interview we discuss lung cancer prevention, the recent low-dose CT screening recommendations from the USPSTF, hurdles in preventing the disease, and more.

A new review describes how increasing prices on cigarettes could be one of the most effective methods in the coming decades for reducing tobacco-related mortality.

I would like to suggest three ways that oncology healthcare professionals can make a difference: help patients quit tobacco use, take an increased presence in tobacco control efforts, and embrace tobacco-free environments.

An analysis of data from the National Lung Screening Trial found that more than 18% of all lung cancers detected through low-dose CT screening were indolent.

The USPSTF published its final recommendation on screening for lung cancer on December 31, concluding that all people between the ages of 55 and 80 years who are at high risk for lung cancer should undergo low-dose CT screening.

Mesotheliomas that arise after patients receive radiation therapy for lymphoma have unusual histologic features, and those patients tend to be younger and tend to survive longer than more common asbestos-related mesothelioma patients.

Combining both cetuximab and bevacizumab with platinum-based chemotherapy showed strong efficacy in a phase II trial of patients with advanced non-small-cell lung cancer.

The International Union Against Tuberculosis and Lung Disease issued a new position statement in November on e-cigarettes and electronic nicotine delivery systems, calling for stricter regulation of these products, which are rapidly growing in popularity.

On November 19, New York City Mayor Michael Bloomberg signed legislation (Tobacco 21 [Intro 250-A]) making New York the first major city to ban the sale of cigarettes, certain tobacco products, and e-cigarettes to anyone under 21 years of age, up from age 18.

Costs associated with cancer care vary widely between countries of the European Union, lung cancer represented the largest cost by individual malignancy, followed by breast and colorectal cancers.

Dose-escalated hypofractionated radiotherapy yielded a maximum tolerated dose for patients with locally advanced non-small-cell lung cancer (NSCLC) and shed light on dangerous toxicity at higher doses, according to a new study.

The tobacco industry has, in effect, caused the biggest toxic spill in history, one that has very literally killed millions of Americans. It is time that the courts compel the industry to clean up their mess.

A blood test that detects a combination of proteins can distinguish between early lung cancer and noncancerous lung nodules, according to a new study.

A combination regimen of erlotinib and the selective MET inhibitor tivantinib did not improve overall survival compared with erlotinib and placebo among patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer.

A novel agent that inhibits the PD-1/PD-L1 pathway showed good results in particular among smokers with non-small-cell lung cancer, a particularly promising result from a phase I trial.

A phase III study of the therapeutic lung cancer vaccine belagenpumatucel-L (Lucanix) failed to meet its predefined endpoint, but the vaccine showed a “considerable” increase in overall survival in patients with non–small-cell lung cancer.

Researchers used an unbiased bioinformatics approach to identify a class of drugs currently used for non-cancer treatment that could be used to treat small-cell lung cancer, a cancer type for which there are few treatment options.

A specific pair of proteins more often found in aggressive smoking-related lung adenocarcinomas could serve as a prognostic biomarker for aggressive disease.